DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Proteomic polygenic risk scores of age-related plasma protein levels reveal a role for Metalloproteinase inhibitor 2 (TIMP2) in cognitive performance
Several studies in mice have identified blood proteins that influence brain aging, yet translating these findings into humans remains challenging. To address this gap, we conducted a systematic review that identified 12 proteins reported to have an aging or rejuvenating effect in murine brains. Using protein quantitative trait loci data, we computed proteomic polygenic risk scores (protPRSs) capturing the lifelong genetic predisposition to higher or lower plasma protein levels and their regulation. We first validated the prediction accuracy of these protPRSs in two independent cohorts: 10 protPRSs in the Knight-ADRC and 7 protPRSs in the ALFA+ cohort significantly predicted their corresponding protein levels, although effect sizes were modest. We then examined their association with cognitive performance in cognitively unimpaired individuals at risk of Alzheimer's disease of the ALFA+ cohort. Among the protPRSs tested, the metalloproteinase inhibitor 2 (TIMP2) protPRS was significantly associated with better global cognition and episodic memory. These associations were consistent across stratifications by sex, APOE-ε4, and amyloid-β status, although some did not survive multiple testing corrections. TIMP2 protPRS correlated with measured TIMP2 levels, but actual plasma concentrations were not significantly related to cognition. This finding aligns with murine evidence of TIMP2's brain-rejuvenating role. By leveraging genetic predisposition to protein abundance and regulation, protPRSs may provide complementary insight into long-term biological processes not captured by single protein measurements. Our results support TIMP2 as a candidate for further investigation in the context of brain aging and cognitive decline., The research leading to these results has received funding from “la Caixa” Foundation, under agreement LCF/PR/SC22/68000001, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016–2020 grant# SLT002/16/00201) and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913 and 2021 SGR 01137. FA receives funding from the JDC2022–049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. This work was supported in part by grants from the National Institutes of Health (R01AG044546 (CC), P01AG003991(CC), RF1AG053303 (CC), RF1AG058501 (CC), U01AG058922 (CC), the Chan Zuckerberg Initiative (CZI), the Alzheimer’s Association Zenith Fellows Award (ZEN-22–848604, awarded to CC), and an Anonymous foundation. The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444 (JCM), P01AG03991(JCM), and P01AG026276(JCM). This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/)and the Departments of Neurology and Psychiatry at Washington University School of Medicine. MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021–184); Project "PI19/00155" and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). NV-T was supported by the Spanish Ministry of Science and Innovation - State Research Agency (IJC2020–043216-I/MCIN/AEI/10.13039/501100011033) and the European Union «NextGenerationEU» /PRTR and currently receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022–038136-I cofunded by the European Union FSE+ and grant PID2022–143106OA-I00 cofunded by the European Union FEDER). Additionally, NV-T is supported in part by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 JDC2022-049347-I
,
EC / H2020 948677
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PI19-00155
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PI22
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 RYC2022-038136-I
DOI: http://hdl.handle.net/10261/446912, https://api.elsevier.com/content/abstract/scopus_id/105022150593
HANDLE: http://hdl.handle.net/10261/446912, https://api.elsevier.com/content/abstract/scopus_id/105022150593